FI953529A0 - Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta - Google Patents
Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainettaInfo
- Publication number
- FI953529A0 FI953529A0 FI953529A FI953529A FI953529A0 FI 953529 A0 FI953529 A0 FI 953529A0 FI 953529 A FI953529 A FI 953529A FI 953529 A FI953529 A FI 953529A FI 953529 A0 FI953529 A0 FI 953529A0
- Authority
- FI
- Finland
- Prior art keywords
- vaccine
- ganglioside
- subject
- provides
- production
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 11
- 150000002270 gangliosides Chemical class 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000016784 immunoglobulin production Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001542 oligosaccharide Polymers 0.000 abstract 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US926893 | 1992-08-07 | ||
| US926893A | 1993-01-22 | 1993-01-22 | |
| PCT/US1994/000757 WO1994016731A1 (en) | 1993-01-22 | 1994-01-21 | Ganglioside-klh conjugate vaccines with qs-21 |
| US9400757 | 1994-01-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI953529A0 true FI953529A0 (fi) | 1995-07-21 |
| FI953529L FI953529L (fi) | 1995-09-15 |
| FI117668B FI117668B (fi) | 2007-01-15 |
Family
ID=21736616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI953529A FI117668B (fi) | 1993-01-22 | 1995-07-21 | Menetelmä gangliosidi-KLH-konjugaattia ja QS-21-ainetta sisältävän koostumuksen valmistamiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US7014856B1 (fi) |
| EP (2) | EP0680338B1 (fi) |
| JP (1) | JP3852945B2 (fi) |
| KR (1) | KR100307289B1 (fi) |
| AT (2) | ATE372783T1 (fi) |
| AU (1) | AU685776B2 (fi) |
| CA (1) | CA2154488C (fi) |
| DE (2) | DE69432513T2 (fi) |
| DK (1) | DK0680338T3 (fi) |
| ES (1) | ES2196024T3 (fi) |
| FI (1) | FI117668B (fi) |
| HK (1) | HK1014659A1 (fi) |
| HU (1) | HU221420B1 (fi) |
| NO (1) | NO318920B1 (fi) |
| NZ (2) | NZ314058A (fi) |
| WO (1) | WO1994016731A1 (fi) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0680338B1 (en) * | 1993-01-22 | 2003-04-16 | Sloan-Kettering Institute For Cancer Research | Ganglioside-klh conjugate vaccines with qs-21 |
| CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
| US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
| US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| US5612030A (en) | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| WO1997040140A1 (en) * | 1996-04-22 | 1997-10-30 | The Wistar Institute Of Anatomy And Biology | Gd2 anti-idiotypic antibodies and uses thereof |
| US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| AUPO732997A0 (en) * | 1997-06-12 | 1997-07-03 | Csl Limited | Ganglioside immunostimulating complexes and uses thereof |
| EP1017419A4 (en) * | 1997-09-25 | 2004-12-29 | Sloan Kettering Institutefor C | FUCOSYL-GM1-KLH CONJUGATE VACCINE AGAINST SMALL CELL LUNG CANCER |
| US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
| EP1903114A3 (en) | 1997-12-01 | 2008-07-23 | Neose Technologies, Inc. | Enzymatic synthesis of gangliosides |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| ATE356140T1 (de) | 2000-04-25 | 2007-03-15 | Otsuka Pharma Co Ltd | Gd3 mimetische peptide |
| EP1731161B1 (en) * | 2000-12-22 | 2014-08-06 | Lpath, Inc. | Sphingosine-1-phosphate antibodies for the treatment of diseases associated with elevated sphingolipid concentrations |
| AU2002357359B2 (en) | 2001-12-21 | 2009-01-08 | Csl Limited | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| ES2294535T3 (es) * | 2003-08-12 | 2008-04-01 | Lipoxen Technologies Limited | Derivados del acido polisialico. |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| CA2593191A1 (en) * | 2005-01-14 | 2006-07-20 | Avax Technologies, Inc. | Method for producing a vaccine for the treatment of cancer |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US20080138334A1 (en) * | 2006-05-31 | 2008-06-12 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same |
| US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
| US9274129B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2009124294A2 (en) * | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| WO2009132082A2 (en) * | 2008-04-22 | 2009-10-29 | Medical College Of Georgia Research Institute, Inc. | Immunogenic compositions containing ceramide and methods of use thereof |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US8512939B2 (en) * | 2009-09-25 | 2013-08-20 | Taiwan Semiconductor Manufacturing Company, Ltd. | Photoresist stripping technique |
| WO2012081508A1 (ja) * | 2010-12-13 | 2012-06-21 | 日本ケミカルリサーチ株式会社 | スフィンゴ糖脂質の定量法 |
| CN106414472A (zh) * | 2013-12-06 | 2017-02-15 | 现实制药有限公司 | 用于靶向癌症和产生抗体的抗神经节苷脂化合物 |
| SI3154583T1 (sl) | 2014-06-04 | 2021-05-31 | Biontech Research And Development, Inc. | Humana monoklonalna protitelesa na gangliozid GD2 |
| US11786586B2 (en) | 2016-12-23 | 2023-10-17 | Aoa Dx | Carbohydrate structures and uses thereof |
| BR112020010635A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | extração de saponina |
| WO2020245207A1 (en) * | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
| WO2023212741A1 (en) * | 2022-04-29 | 2023-11-02 | Seneb Biosciences, Inc. | Treatment of gm1 deficiencies |
| WO2024238940A1 (en) * | 2023-05-17 | 2024-11-21 | Regents Of The University Of Minnesota | Vaccine compositions and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4591552A (en) * | 1982-09-29 | 1986-05-27 | New York Blood Center, Inc. | Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide |
| US4557931A (en) * | 1982-12-02 | 1985-12-10 | Regents Of The University Of California | Antigenic compositions and methods for using same |
| US4652629A (en) * | 1985-07-03 | 1987-03-24 | The Salk Institute For Biological Studies | Synthetic peptide-based anti-rabies compositions and methods |
| US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| US5344870A (en) * | 1987-12-02 | 1994-09-06 | Alberta Research Council | Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation |
| US5102663A (en) | 1988-10-18 | 1992-04-07 | Sloan-Kettering Instutute For Cancer Research | Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3 |
| DE3840044A1 (de) | 1988-11-27 | 1990-06-07 | Behringwerke Ag | Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung |
| GB9001694D0 (en) * | 1990-01-25 | 1990-03-28 | Therapeutic Antibodies Inc | Immunogenic compositions |
| EP0680338B1 (en) * | 1993-01-22 | 2003-04-16 | Sloan-Kettering Institute For Cancer Research | Ganglioside-klh conjugate vaccines with qs-21 |
| AU686840B2 (en) | 1994-07-07 | 1998-02-12 | Immunex Corporation | Fusion proteins comprising GM-CSF and antigens and their expression in yeast |
-
1994
- 1994-01-21 EP EP94907279A patent/EP0680338B1/en not_active Expired - Lifetime
- 1994-01-21 DE DE69432513T patent/DE69432513T2/de not_active Expired - Lifetime
- 1994-01-21 US US08/196,154 patent/US7014856B1/en not_active Expired - Lifetime
- 1994-01-21 AU AU60924/94A patent/AU685776B2/en not_active Expired
- 1994-01-21 WO PCT/US1994/000757 patent/WO1994016731A1/en active IP Right Grant
- 1994-01-21 CA CA002154488A patent/CA2154488C/en not_active Expired - Lifetime
- 1994-01-21 AT AT03008652T patent/ATE372783T1/de not_active IP Right Cessation
- 1994-01-21 EP EP03008652A patent/EP1360963B1/en not_active Expired - Lifetime
- 1994-01-21 DK DK94907279T patent/DK0680338T3/da active
- 1994-01-21 NZ NZ314058A patent/NZ314058A/xx not_active IP Right Cessation
- 1994-01-21 NZ NZ261744A patent/NZ261744A/en not_active IP Right Cessation
- 1994-01-21 ES ES94907279T patent/ES2196024T3/es not_active Expired - Lifetime
- 1994-01-21 KR KR1019950703022A patent/KR100307289B1/ko not_active IP Right Cessation
- 1994-01-21 AT AT94907279T patent/ATE237357T1/de active
- 1994-01-21 JP JP51720394A patent/JP3852945B2/ja not_active Expired - Lifetime
- 1994-01-21 DE DE69435025T patent/DE69435025D1/de not_active Expired - Lifetime
- 1994-01-21 HU HU9502201A patent/HU221420B1/hu unknown
-
1995
- 1995-06-07 US US08/477,097 patent/US6936253B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/477,147 patent/US7001601B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/481,809 patent/US6916476B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,784 patent/US6967022B1/en not_active Expired - Lifetime
- 1995-07-21 NO NO19952914A patent/NO318920B1/no not_active IP Right Cessation
- 1995-07-21 FI FI953529A patent/FI117668B/fi not_active IP Right Cessation
-
1998
- 1998-12-28 HK HK98116010A patent/HK1014659A1/xx not_active IP Right Cessation
-
2006
- 2006-03-13 US US11/375,549 patent/US20060153859A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI953529A0 (fi) | Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta | |
| PT92938A (pt) | Imunogenes e processo para a preparacao de composicoes imunogenicas contra os peptidos da gastrina | |
| CA2129899A1 (en) | Dual carrier immunogenic construct | |
| BRPI0010612B8 (pt) | vacinas | |
| EP0438803A3 (en) | Vaccines against cancer and infectious diseases | |
| DE60234782D1 (de) | Behandlungsverfahren mit liganden-immunogenkonjugaten | |
| HUP9901254A2 (hu) | Nemdendrites szerkezetű gerincet alkotó peptid hordozó | |
| CY1107571T1 (el) | Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου | |
| CY1111814T1 (el) | Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων | |
| ATE182270T1 (de) | Mukosale verabreichung von pneumokokken-antigenen | |
| FI932759A0 (fi) | Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner | |
| RU95117939A (ru) | Вакцины конъюгатов ганглиозид- klh c qs-21, способ стимулирования продуцирования антител, способ лечения рака, способ предотвращения рака | |
| SE8400934D0 (sv) | Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner | |
| WO2003032895A3 (en) | Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 117668 Country of ref document: FI |
|
| MA | Patent expired |